Nektar Presents Phase 2b Data for Rezpegaldesleukin, Phase 3 to Start Early 2027

Nektar Therapeutics reported durable hair regrowth and deepening responses through one year for rezpegaldesleukin in alopecia areata, with durable maintenance observed in atopic dermatitis. Phase 3 trials for ZENITH AA are set to begin in early 2027.